Advisory Committee on Childhood Lead Poisoning Prevention, 11419-11420 [E8-4085]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 42 / Monday, March 3, 2008 / Notices
378–3160). Oppositions to this petition
must be filed by March 18, 2008. See
Section 1.4(b)(1) of the Commission’s
rules (47 CFR 1.4(b)(1)). Replies to an
opposition must be filed within 10 days
after the time for filing oppositions have
expired.
Subject: In the Matter of Amendment
of the Commission’s Rules Concerning
Maritime Communications (PR Docket
No. 92–257).
Number of Petitions Filed: 1.
Marlene H. Dortch,
Secretary.
[FR Doc. E8–4050 Filed 2–29–08; 8:45 am]
BILLING CODE 6712–01–P
FEDERAL RESERVE SYSTEM
rmajette on PROD1PC64 with NOTICES
Notice of Proposals to Engage in
Permissible Nonbanking Activities or
to Acquire Companies that are
Engaged in Permissible Nonbanking
Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y (12
CFR Part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act. Additional information on all
bank holding companies may be
obtained from the National Information
Center website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than March 31, 2008.
A. Federal Reserve Bank of
Richmond (A. Linwood Gill, III, Vice
President) 701 East Byrd Street,
Richmond, Virginia 23261-4528:
1. Bank of America Corporation,
Charlotte, North Carolina; to acquire
Countrywide Financial Corporation,
Calabasas, California, and thereby
VerDate Aug<31>2005
16:15 Feb 29, 2008
Jkt 214001
indirectly acquire Countrywide Bank,
FSB, Alexandria, Virginia, Countrywide
Home Loans, Inc., Calabasas, California,
Countrywide Financial Corporation,
Calabasas, California, Countrywide
Financial Holding Company, Inc.,
Calabasas, California, Effinity Financial
Corporation, Alexandria, Virginia,
Countrywide Tax Services Corporation,
Simi Valley, California, CTC Real Estate
Services, Calabasas, California,
Countrywide Servicing Exchange,
Calabasas, California, Countrywide
Asset Management Corp., Calabasas,
California, Landsafe Appraisal Services,
Inc., Plano, Texas, Landsafe Credit, Inc.,
Richardson, Texas, Landsafe Flood
Determination, Inc., Richardson, Texas,
Landsafe Title of California, Inc.,
Rosemead, California, Landsafe Title of
Texas, Inc., Rosemead, California,
Landsafe Title of Florida, Inc.,
Calabasas, California, Countrywide
Warehouse Lending, Calabasas,
California, Countrywide Home Loans
Servicing LP, Plano, Texas,
Countrywide Mortgage Ventures, LLC,
Calabasas, California, Countrywide
Commercial Real Estate Finance, Inc.,
Calabasas, California, The Countrywide
Foundation, Calabasas, California,
Recontrust Company, National
Association, Thousand Oaks, California,
CWB Community Assets, Inc.,
Thousand Oaks, California,
Countrywide Commercial
Administration LLC, Calabasas,
California, Recontrust Company
(Nevada) Thousand Oaks, California,
Countrywide KB Home Loans, LLC,
Thousand Oaks, California, CWB
Mortgage Ventures, LLC, Thousand
Oaks, California, Landsafe Services of
Alabama, Inc., Rosemead, California,
Landsafe Title of Maryland, Inc.,
Calabasas, California and thereby engage
in (1) operating a savings association; (2)
operating a nondepository trust
company; (3) community development
activities; (4) extending credit and
servicing loans; (5) real estate and
personal property appraising; (6) credit
bureau services; (7) asset management,
servicing, and collection activities; (8)
acquiring debt in default; and (9)
providing tax services for residential
mortgage transaction pursuant to section
225.28(b)(1), 225.28(b)(2), 225.28(b)(4),
225.28(b)(5), 225.28(b)(6) and
225.28(b)(12) of Regulation Y.
In connection with this proposal Bank
of America Corporation, has applied to
acquire from Bank of America, National
Association, Charlotte, North Carolina,
20,000 shares of Series B Non-Voting
Convertible Preferred Stock of
Countrywide Financial Corporation,
Calabasas, California, which is
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
11419
convertible at the option of the holder
into approximately 15.7 percent of the
voting common stock of Countrywide
Financial Corporation.
Board of Governors of the Federal Reserve
System, February 27, 2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E8–4013 Filed 2–29–08; 8:45 am]
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Childhood
Lead Poisoning Prevention
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting for the
aforementioned committee:
Times and Dates: 8:30 a.m.–5 p.m., March
18, 2008. 8:30 a.m.–12:30 p.m., March 19,
2008.
Place: CDC Global Communication Center,
Roybal Facility, 1600 Clifton Road, Atlanta,
GA 30333, Telephone: (770) 488–3300.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 75 people.
Please Note: Due to current security
measures, a valid government issued
identification card with photo is required for
admittance into the Roybal facility. Non-U.S.
citizens wishing to attend should contact
Claudine Johnson, Telephone: (770) 488–
3629. Individuals should ask for the meeting
by name: CDC Advisory Committee on
Childhood Lead Poisoning Prevention when
they arrive at the Roybal Visitors Center.
Purpose: The Committee provides advice
and guidance to the Secretary; the Assistant
Secretary for Health; and the Director, CDC,
regarding new scientific knowledge and
technological developments and their
practical implications for childhood lead
poisoning prevention efforts. The committee
also reviews and reports regularly on
childhood lead poisoning prevention
practices and recommends improvements in
national childhood lead poisoning
prevention efforts.
Matters To Be Discussed: A discussion on
the potential approaches to strengthen
existing strategies to achieve the Healthy
People 2010 goal of eliminating Elevated
Blood Lead Levels as a public health problem
in the U.S. by 2010; Update the school
performance and concurrent Blood Lead
Levels (BLLs); Discuss the study designs
related to adverse effects from BLLs < 10 µg/
dl; and discuss the development of a
prevention-based research agenda.
Agenda items are subject to change as
priorities dictate. There will be an
opportunity for oral comments during the
meeting. Depending on the time available
E:\FR\FM\03MRN1.SGM
03MRN1
11420
Federal Register / Vol. 73, No. 42 / Monday, March 3, 2008 / Notices
and the number of requests, it may be
necessary to limit the time of each presenter.
Contact Person for More Information:
Claudine Johnson, Clerk, Lead Poisoning
Prevention Branch, Division of
Environmental Emergency Health Services,
National Center for Environmental Health,
CDC, 4770 Buford Hwy., NE., Mailstop F–60,
Atlanta, GA 30341, Telephone: (770) 488–
3629, Fax (770) 488–3635.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: February 27, 2008.
Diane Allen,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E8–4085 Filed 2–29–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–D–0118]
Draft Guidance for Industry on
Diabetes Mellitus: Developing Drugs
and Therapeutic Biologics for
Treatment and Prevention; Availability
AGENCY:
Food and Drug Administration,
HHS.
rmajette on PROD1PC64 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘Diabetes Mellitus:
Developing Drugs and Therapeutic
Biologics for Treatment and
Prevention.’’ The draft guidance
provides recommendations for industry
for developing drugs and therapeutic
biologics for the prevention and
treatment of diabetes mellitus. Because
diabetes mellitus has reached epidemic
proportions in the United States, FDA
recognizes the need for new products
that can be used as part of a
comprehensive treatment strategy in the
treatment and prevention of diabetes. In
addition to the draft guidance, FDA
plans to convene a public advisory
committee meeting to specifically
discuss new approaches for the
development of products for the
treatment of diabetes, with particular
emphasis on the design and
implementation of studies to assess
long-term cardiovascular risks and
benefits of these new products. FDA
plans to announce the meeting date in
a future issue of the Federal Register.
VerDate Aug<31>2005
15:33 Feb 29, 2008
Jkt 214001
Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
written or electronic comments on the
draft guidance by May 2, 2008.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Submit written comments on the draft
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance
document.
FOR FURTHER INFORMATION CONTACT: Ilan
Irony, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 22, rm. 3100, Silver Spring,
MD 20993–0002, 301–796–2290.
SUPPLEMENTARY INFORMATION:
DATES:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Diabetes Mellitus: Developing Drugs
and Therapeutic Biologics for Treatment
and Prevention.’’ Although a number of
drugs are available for the treatment of
type 1 and type 2 diabetes, many
patients remain inadequately controlled,
and thus are exposed to a higher risk of
long-term complications. This draft
guidance provides recommendations on
the following topics related to the
treatment of type 1 and type 2 diabetes
mellitus:
• Diabetes-specific preclinical
studies;
• Different study designs in different
phases of drug development for both
type 1 and type 2 diabetes;
• Study endpoints in the assessment
of pharmacokinetic/pharmacodynamic
profiles and for efficacy and safety
assessment in treating patients with
diabetes;
• Study population considerations in
different phases of development;
• Sample sizes;
• Study duration; and
• Specific statistical issues related to
development of drugs and biologics
intended for the treatment of diabetes.
The draft guidance also provides
recommendations regarding the
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
development of products for the
prevention of both type 1 and type 2
diabetes.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the agency’s current thinking
on the treatment and prevention of
diabetes mellitus. It does not create or
confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Please note that on January 15, 2008,
the FDA Web site transitioned to the
Federal Dockets Management System
(FDMS). FDMS is a Government-wide,
electronic docket management system.
Electronic submissions will be accepted
by FDA through FDMS only.
III. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/cder/guidance/
index.htm or https://www.fda.gov/
ohrms/dockets/default.htm.
Dated: February 25, 2008.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E8–3974 Filed 2–29–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Organ Procurement and
Transplantation Network
Health Resources and Services
Administration (HRSA), HHS.
ACTION: Request for information.
AGENCY:
SUMMARY: HRSA, Healthcare Systems
Bureau, Division of Transplantation
(DoT) is in the process of information-
E:\FR\FM\03MRN1.SGM
03MRN1
]]>Agencies
[Federal Register Volume 73, Number 42 (Monday, March 3, 2008)]
[Notices]
[Pages 11419-11420]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-4085]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Childhood Lead Poisoning Prevention
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting for the
aforementioned committee:
Times and Dates: 8:30 a.m.-5 p.m., March 18, 2008. 8:30 a.m.-
12:30 p.m., March 19, 2008.
Place: CDC Global Communication Center, Roybal Facility, 1600
Clifton Road, Atlanta, GA 30333, Telephone: (770) 488-3300.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 75 people. Please Note:
Due to current security measures, a valid government issued
identification card with photo is required for admittance into the
Roybal facility. Non-U.S. citizens wishing to attend should contact
Claudine Johnson, Telephone: (770) 488-3629. Individuals should ask
for the meeting by name: CDC Advisory Committee on Childhood Lead
Poisoning Prevention when they arrive at the Roybal Visitors Center.
Purpose: The Committee provides advice and guidance to the
Secretary; the Assistant Secretary for Health; and the Director,
CDC, regarding new scientific knowledge and technological
developments and their practical implications for childhood lead
poisoning prevention efforts. The committee also reviews and reports
regularly on childhood lead poisoning prevention practices and
recommends improvements in national childhood lead poisoning
prevention efforts.
Matters To Be Discussed: A discussion on the potential
approaches to strengthen existing strategies to achieve the Healthy
People 2010 goal of eliminating Elevated Blood Lead Levels as a
public health problem in the U.S. by 2010; Update the school
performance and concurrent Blood Lead Levels (BLLs); Discuss the
study designs related to adverse effects from BLLs < 10 [mu]g/dl;
and discuss the development of a prevention-based research agenda.
Agenda items are subject to change as priorities dictate. There
will be an opportunity for oral comments during the meeting.
Depending on the time available
[[Page 11420]]
and the number of requests, it may be necessary to limit the time of
each presenter.
Contact Person for More Information: Claudine Johnson, Clerk,
Lead Poisoning Prevention Branch, Division of Environmental
Emergency Health Services, National Center for Environmental Health,
CDC, 4770 Buford Hwy., NE., Mailstop F-60, Atlanta, GA 30341,
Telephone: (770) 488-3629, Fax (770) 488-3635.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: February 27, 2008.
Diane Allen,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. E8-4085 Filed 2-29-08; 8:45 am]
BILLING CODE 4163-18-P
